North America Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Disease Indication (Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Others), By Drug Type (Immunomodulator, Vesicular Monoamine Transporter 2 (VMAT2), Others), By Routes of Administration (Oral, Intravenous (IV) delivery, Others) and By Country (US, Canada) Forecasts, 2026-2034

Market Overview

The worldwide neurodegenerative disease market size was valued at USD 25.01 billion in 2025 and is estimated to grow from USD 26.65 billion in 2026 to reach USD 44.23 billion by 2034, growing at a CAGR of 6.54% during the forecast period (2026–2034).

In most cases, neurodegenerative disorders are characterised by gradual nerve cell degeneration that can occur in a variety of locations across the body. Loss of memory and cognitive control are potential outcomes of a number of conditions, including Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), and amyotrophic lateral sclerosis (ALS).

Although there are very few diseases that can be cured, the pharmaceutical industry has developed a variety of treatments throughout the years that aim to alleviate the symptoms of neurodegenerative ailments.

Neurodegenerative disorders are a varied group of ailments defined by the gradual degradation of the function and structure of the central nervous system or peripheral nervous system. Neurodegenerative disorders, including Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, and Huntington's disease, have been rising globally. Thus, the growing burden of this condition is the key driver driving the market expansion, adding to it the expanding elderly population. According to NIH, nearly 1.2 million people in the United States will have Parkinson's disease by 2030. In the United States, it is the second most frequent neurodegenerative disorder.

Furthermore, according to Alzheimer's Disease International, more than 50 million adults with dementia globally in 2020. This number is anticipated to be more than double every two decades, reaching 82 million in 2030 and 152 million in 2050. Additionally, much of the increase will be in emerging countries. About 60% of persons with dementia reside in poor and middle-income nations, but by 2050, this will climb to 71%. The fastest rise in the senior population has happened in China, India, and South Asian and western Pacific countries. Thus, the growing burden of dementia is likely to enhance the market growth in the approaching years.

North America Neurodegenerative Disease Market Segmental Analysis

By Disease Indication

The North America neurodegenerative disease market is segmented by disease indication into multiple sclerosis, Parkinson's disease, Alzheimer's disease, and others. Multiple sclerosis represents an important treatment area due to the continuing need for disease management and disease-modifying therapies. Parkinson's disease is also generating sustained demand as the region's aging population increases the prevalence of progressive movement and neurological disorders. Alzheimer's disease is gaining considerable attention because of the growing number of older adults, increasing focus on cognitive health, and advancements in diagnosis and treatment. Greater availability of neurologists, specialized treatment centers, and advanced diagnostic technologies is supporting the identification and management of these conditions across the United States and Canada.

The others category includes additional neurodegenerative and neurological disorders that require specialized diagnosis, medication, and long-term clinical management. Expansion of neurological research, improved understanding of disease mechanisms, and increasing investment in innovative therapies are creating opportunities across this segment. North America's well-developed healthcare infrastructure, extensive specialist network, and strong pharmaceutical research environment support the adoption of advanced treatment options. However, differences in insurance coverage, treatment costs, reimbursement policies, and access to specialized care can influence patient access and therapeutic adoption across the region.

Request Customizationto receive a tailored report.

By Drug Type

The North America neurodegenerative disease market is categorized by drug type into immunomodulator, vesicular monoamine transporter 2 (VMAT2), and others. Immunomodulators play an important role in neurological conditions where immune-system activity contributes to disease development or progression, while VMAT2-targeted therapies address specific neurotransmitter-related mechanisms associated with neurological and movement disorders. Growing clinical understanding of disease pathways and increasing availability of specialized therapies are supporting the use of these drug types. The presence of advanced research institutions and pharmaceutical companies in North America is also encouraging the development of treatments with novel mechanisms of action.

The others segment includes therapeutic drugs that do not fall within immunomodulators or VMAT2-targeted treatments. These medicines can be used for symptom management, disease control, or targeting specific neurological mechanisms depending on the condition being treated. Continued pharmaceutical research and clinical development are expanding the range of potential therapeutic approaches available to patients. Market adoption is influenced by regulatory approvals, clinical evidence, physician prescribing practices, reimbursement coverage, treatment pricing, and patient access. The established healthcare and pharmaceutical ecosystem in North America provides favorable conditions for the commercialization of innovative neurodegenerative disease therapies.

By Routes of Administration

The North America neurodegenerative disease market is segmented by routes of administration into oral, intravenous (IV) delivery, and others. Oral administration remains an important route because tablets and capsules offer convenience for patients requiring long-term therapy and can generally be administered outside hospital settings. This route supports outpatient treatment and can simplify medication routines for patients and caregivers. Intravenous (IV) delivery is used for therapies that require direct administration into the bloodstream, controlled dosing, or professional medical supervision. The region's extensive network of hospitals, specialty clinics, and infusion centers supports the use of IV therapies when clinically appropriate.

The others category includes alternative administration methods that may provide specific benefits depending on the drug formulation, treatment objective, and patient's condition. Advances in pharmaceutical formulation and drug-delivery technologies are creating opportunities for approaches designed to improve drug absorption, maintain therapeutic exposure, and enhance patient convenience. The selection of an administration route depends on factors such as disease severity, drug characteristics, patient needs, and physician recommendations. In North America, adoption of different delivery methods is further influenced by healthcare infrastructure, reimbursement coverage, treatment costs, regulatory requirements, and the introduction of specialized neurological therapies.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The research indicates that the North America area has a significant lead in the industry being examined, with projected revenues of USD 16,915 million in 2021. It is anticipated that by the year 2030, its value would have increased to USD 21,125 million, representing a compound annual growth rate (CAGR) of 2.5% throughout the period being forecasted. The rise in funding for different studies related neurodegenerative illnesses, the rise in disease incidence and awareness, and the presence of important market participants are the aspects that are responsible for the expansion of the market for neurodegenerative disorders in the United States.

The presence of a large number of drug manufacturers and an evolving paradigm of care for patients with neurodegenerative diseases, which is supporting growth in this region, are expected to cause North America to dominate the market. This is one of the reasons why the market is expected to grow in North America. For instance, the United States Food and Drug Administration (FDA) granted approval to Merck & Co., Inc. in February 2020 for an update to the prescribing information for BELSOMRA (suvorexant) C-IV. This update included findings on the use of the medication to treat insomnia in patients with mild-to-moderate Alzheimer's disease. A number of factors have contributed to the expansion of the neurodegenerative illness market in the area, including recent developments in cutting-edge technology for the treatment of neurodegenerative disorders and a robust product pipeline for wasting syndrome. As a result of the aforementioned reasons, it is predicted that the researched market would see considerable growth in North America throughout the course of the forecast period.

List of Key and Emerging Players in North America Neurodegenerative Disease Market